Marietta Memorial Hospital | Department of Rheumatology

Research site
800 Wayne Street Suite 100, Marietta, Ohio, United States of America
Site insights

Top conditions

Carcinoma (95 trials)

Breast Cancer (42 trials)

Lung Cancer (39 trials)

Adenocarcinoma (34 trials)

Recurrence (33 trials)

Top treatments

Gemcitabine Hydrochloride
Erlotinib Hydrochloride

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


12 of 250
Status: Active
Trial type: Interventional
Funder type: Industry

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo
Locations recently updated

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting
Drug: Placebo
Drug: Upadacitinib

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Stage III Colon Cancer
Drug: mFOLFOX6 6 month
Drug: mFOLFOX6 3-6 month

This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well...

Active, not recruiting
Solitary Osseous Plasmacytoma
Drug: dexamethasone
Drug: lenalidomide

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to se...

Active, not recruiting
Multiple Myeloma in Relapse
Drug: ixazomib
Drug: dexamethasone

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting
Colorectal Neoplasms
Drug: eflornithine & sulindac placebo
Drug: Eflornithine placebo & sulindac placebo

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen depriva...

Active, not recruiting
Prostate Cancer
Drug: Bicalutamide
Drug: TAK-700

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab/rHuPH20

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with me...

Recurrent Meningioma
NF2 Gene Mutation
Drug: Abemaciclib
Drug: Vismodegib

Trial sponsors

National Cancer Institute (NCI) logo

National Cancer Institute (NCI) (129 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems